Sandoz
Austria - Kundl
Biotechnology2 H-1B visas (FY2023)Focus: Generics, Biosimilars
Sandoz is a life sciences company focused on Generics, Biosimilars.
ImmunologyInfectious DiseasesNeurologyCardiovascularRespiratory
Funding Stage
PUBLIC
Open Jobs
0
Products & Portfolio (40)
10 discontinued products not shown
ACYCLOVIR
acyclovir
Post-LOE
SMTOPICAL · OINTMENT
CLINICAL PHARMACOLOGY Pharmacokinetics: The pharmacokinetics of acyclovir after oral administration have been evaluated in healthy volunteers and in immunocompromised patients with herpes simplex or varicella-zoster virus infection. Acyclovir pharmacokinetic parameters are summarized in Table 1. Table 1. Acyclovir Pharmacokinetic Characteristics (Range) Bioavailability decreases with increasing dose. Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2. The decrease in bioavailability is a function of the dose and not the dosage form. Table 2. Acyclovir Peak and Trough Concentrations at Steady State Parameter 200 mg 400 mg 800 mg C m a x 0.83 mcg/mL 1.21 mcg/mL 1.61 mcg/mL C t r o u g h 0.46 mcg/mL 0.63 mcg/mL 0.83 mcg/mL There was no effect of food on the absorption of acyclovir (n = 6); therefore, Acyclovir Tablets may be administered with or without food. The only known urinary metabolite is 9-[(carboxymethoxy)methyl]guanine. Special Populations: Adults With Impaired Renal Function: The half-life and total body clearance of acyclovir are dependent on renal function. A dosage adjustment is recommended for patients with reduced renal function ( ). Geriatrics: Acyclovir plasma concentrations are higher in geriatric patients compared with younger adults, in part due to age-related changes in renal function. Dosage reduction may be required in geriatric patients with underlying renal impairment ( ). Pediatrics: In general, the pharmacokinetics of acyclovir in pediatric patients is similar to that of adults. Mean half-life after oral doses of 300 mg/m and 600 mg/m in pediatric patients aged 7 months to 7 years was 2.6 hours (range 1.59 to 3.74 hours). Drug Interactions: Coadministration of probenecid with intravenous acyclovir has been shown to increase the mean acyclovir half-life and the area under the concentration-time curve. Urinary excretion and renal clearance were correspondingly reduced. Clinical Trials: Initial Genital Herpes: Double-blind, placebo-controlled studies have demonstrated that orally administered acyclovir significantly reduced the duration of acute infection and duration of lesion healing. The duration of pain and new lesion formation was decreased in some patient groups. Recurrent Genital Herpes: Double-blind, placebo-controlled studies in patients with frequent recurrences (6 or more episodes per year) have shown that orally administered acyclovir given daily for 4 months to 10 years prevented or reduced the frequency and/or severity of recurrences in greater than 95% of patients. In a study of patients who received acyclovir 400 mg twice daily for 3 years, 45%, 52%, and 63% of patients remained free of recurrences in the first, second, and thi
initial episodesthe management of recurrent episodes of genital herpeschickenpox (varicella)
2016
30
ADAPALENE
adapalene
Post-LOE
TOPICAL · CREAM
Mechanism of Action: Adapalene acts on retinoid receptors. Biochemical and pharmacological profile studies have demonstrated that adapalene is a modulator of cellular differentiation, keratinization, and inflammatory processes all of which represent important features in the pathology of acne vulgaris. Mechanistically, adapalene binds to specific retinoic acid nuclear receptors but does not bind to the cytosolic receptor protein. Although the exact mode of action of adapalene is unknown, it is suggested that topical adapalene normalizes the differentiation of follicular epithelial cells resulting in decreased microcomedone formation.
2010
30
ALCLOMETASONE DIPROPIONATE
alclometasone dipropionate
Post-LOE
TOPICAL · OINTMENT
CLINICAL PHARMACOLOGY Like other topical corticosteroids, alclometasone dipropionate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A 2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A 2 . Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusive dressings with hydrocortisone for up to 24 hours have not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption. A study utilizing a radio labeled alclometasone dipropionate ointment formulation was performed to measure systemic absorption and excretion. Results indicated that approximately 3% of the steroid was absorbed during 8 hours of contact with intact skin of normal volunteers. Studies performed with alclometasone dipropionate ointment indicate that this product is in the low to medium range of potency as compared with other topical corticosteroids.
2005
30
ALCLOMETASONE DIPROPIONATE
alclometasone dipropionate
Post-LOE
TOPICAL · CREAM
CLINICAL PHARMACOLOGY: Like other topical corticosteroids, alclometasone dipropionate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A 2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A 2 . Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusive dressings with hydrocortisone for up to 24 hours have not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption. A study utilizing a radio labeled alclometasone dipropionate cream formulation was performed to measure systemic absorption and excretion. Results indicated that approximately 3% of the steroid was absorbed during 8 hours of contact with intact skin of normal volunteers. Studies performed with alclometasone dipropionate cream indicate that this product is in the low to medium range of potency as compared with other topical corticosteroids.
2005
30
BETAMETHASONE DIPROPIONATE
betamethasone dipropionate
Post-LOE
TOPICAL · LOTION, AUGMENTED
signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action of betamethasone dipropionate lotion (augmented), 0.05% in corticosteroid responsive dermatoses is unknown.
2007
30
BETAMETHASONE DIPROPIONATE
betamethasone dipropionate
Post-LOE
TOPICAL · GEL, AUGMENTED
[see ] . Betamethasone dipropionate is a corticosteroid. Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action for the treatment of tinea pedis, tinea cruris and tinea corporis is unknown.
2003
30
BETAMETHASONE DIPROPIONATE
betamethasone dipropionate
LOE Approaching
TOPICAL · OINTMENT
CLINICAL PHARMACOLOGY: Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids (See ). Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
1984
30
BETAMETHASONE DIPROPIONATE
betamethasone dipropionate
LOE Approaching
TOPICAL · CREAM
CLINICAL PHARMACOLOGY: Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids (See ). Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
1984
30
BETAMETHASONE DIPROPIONATE
betamethasone dipropionate
Post-LOE
TOPICAL · OINTMENT, AUGMENTED
signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action of betamethasone dipropionate ointment (augmented), 0.05% in corticosteroid responsive dermatoses is unknown.
1999
30
BETAMETHASONE DIPROPIONATE
betamethasone dipropionate
Post-LOE
TOPICAL · LOTION
CLINICAL PHARMACOLOGY: Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids (See ). Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
1985
30
BETAMETHASONE DIPROPIONATE
betamethasone dipropionate
Post-LOE
TOPICAL · CREAM, AUGMENTED
[see ] . Betamethasone dipropionate is a corticosteroid. Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action for the treatment of tinea pedis, tinea cruris and tinea corporis is unknown.
2003
30
BETAMETHASONE VALERATE
betamethasone valerate
LOE Approaching
TOPICAL · OINTMENT
CLINICAL PHARMACOLOGY: Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses. Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
1983
30
Pipeline & Clinical Trials
The Mycophenolate Pregnancy Registry
Heart Transplantation, Kidney Transplantation, Liver Transplantation, Autoimmune DiseasesZidovudine
HIV InfectionsClinical Trials (1)
NCT00002007A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and Leukopenia
N/AHyrimoz
Inflammatory Bowel DiseaseClinical Trials (1)
NCT05633771Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting
N/AReal-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s Diseas
Crohn´s DiseaseClinical Trials (1)
NCT03890445Real-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s Disease
N/AIn this observational study no study specific intervention is planned
Chronic Kidney InsufficiencyClinical Trials (1)
NCT01353417Non-interventional-study With Tacrolimus Sandoz© Capsules for Prophylaxis of Renal Graft Rejection
N/AMulti-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determ
Febrile NeutropeniaClinical Trials (1)
NCT01459653Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
N/Anon-interventional
PsoriasisClinical Trials (1)
NCT02668341Cross Sectional Analysis of Healthcare for Psoriasis in 4 European Countries
N/ANon-interventional, Long-term Safety Data Collection of Zarzio® / Filgrastim HEXAL® in Stem Cell Don
Hematopoietic Stem Cell MobilizationClinical Trials (1)
NCT01766934Non-interventional, Long-term Safety Data Collection of Zarzio® / Filgrastim HEXAL® in Stem Cell Donors
N/AInterleukin-3
HIV InfectionsGeneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions
DepressionClinical Trials (1)
NCT00913952To Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed and Fasted Conditions
Phase 1Cefdinir 250 mg/5 ml Oral Suspension
HealthyClinical Trials (1)
NCT00882570To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250mg/5 ml Oral Suspension Fasting Conditions
Phase 1Atenolol Tablets 100 mg
HypertensionClinical Trials (1)
NCT00913965To Demonstrate the Relative Bioavailability of Atenolol Tablets
Phase 1Fluoxetine Hydrochloride Capsules, 40 mg
DepressionClinical Trials (1)
NCT00947076To Demonstrate the Relative Bioavailability of Fluoxetine Hydrochloride Capsules, 40 mg
Phase 1Hydroxychloroquine Sulfate Tablets, 200 mg
ImmunosuppressionClinical Trials (1)
NCT00946790To Demonstrate the Relative Bioavailability of Hydroxychloroquine Sulfate, 200 mg Tablets
Phase 1Clomipramine Hydrochloride 25 mg Capsules
DepressionClinical Trials (1)
NCT00913783To Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fasted Conditions
Phase 1Desipramine HCL 100 mg Tablets Cord Laboratories
DepressionClinical Trials (1)
NCT00913809To Demonstrate the Relative Bioequivalency of Cord's 100 mg Desipramine HCL Tablets To Merrell Dow's 100 mg Norpramin Tablets
Phase 1Haloperidol 10 mg Tablets
PsychosisClinical Trials (1)
NCT00946491To Demonstrate the Relative Bioequivalency of Generic Haloperidol Tablets Versus Haldol in Normal Volunteers
Phase 1Cefprozil 500 mg Tablets
HealthyClinical Trials (1)
NCT00881855To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fed Conditions
Phase 1Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC
Type II DiabetesClinical Trials (1)
NCT00882882To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting Conditions
Phase 1Nadolol
High Blood PressureClinical Trials (1)
NCT00960245Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions
Phase 1Cefprozil 250 mg/5 ml Oral Suspension
HealthyClinical Trials (1)
NCT00881400To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Fed Conditions
Phase 1Sevirumab
Cytomegalovirus RetinitisClinical Trials (1)
NCT00002016A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis
Phase 1Budesonide
Healthy VolunteersClinical Trials (1)
NCT05429775In Vivo Performance of Oral Liquid Formulations of Budesonide in the Fasted State in Healthy Subjects
Phase 1Asmakast
HealthyClinical Trials (1)
NCT02479854Bioequivalence Study of Montelukast From Asmakast 5mg Chewable Tab.(Sandoz, Egypt) & Singulair 5mg Chewable Tab.(Merck)
Phase 1Cilostazol 50 mg Tablets
PainClinical Trials (1)
NCT00881231To Demonstrate the Relative Bioavailability of Cilostazol 50 mg Tablets Under Fasting Conditions
Phase 1Desipramine Hydrochloride 50 mg Tablets
DepressionClinical Trials (1)
NCT00913237To Demonstrate the Relative Bioavailability of Desipramine Hydrochloride 50 mg Tablets
Phase 1Lisinopril 40 mg Tablet
HypertensionClinical Trials (1)
NCT00883064To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablets Under Fasting Conditions
Phase 1Azithromycin Monohydrate 600mg Tablets Geneva Pharmaceuticals
InfectionClinical Trials (1)
NCT00866216Comparative Bioavailability Study of 600mg Azithromycin Monohydrate Tablets Under Fasting Conditions
Phase 1Sevirumab
Cytomegalovirus InfectionsClinical Trials (1)
NCT00002268A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria
Phase 1Naproxen Delayed Release Tables, 375
Rheumatoid ArthritisClinical Trials (1)
NCT00959439Relative Bioavailability Study of Naproxen Delayed-Release Tablets (375 mg)
Phase 1Desipramine Hydrochloride 100 mg Tablets
DepressionClinical Trials (1)
NCT00913822To Demonstrate the Relative Bioavailability of Desipramine Hydrochloride Tablets
Phase 1Asmakast
HealthyClinical Trials (1)
NCT02480049A Bioequivalence Study of Montelukast From Asmakast 10mg Tabs (Sandoz, Egypt) & Singulair 10mg Tabs (Merck)
Phase 1Leflunomide 20 mg Tablets
Rheumatoid ArthritisClinical Trials (1)
NCT00946686To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions
Phase 1Clarithromycin 250 mg Tablets
HealthyClinical Trials (1)
NCT00881738To Demonstrate the Relative Bioavailability of Clarithromycin 250 mg Tablets Under Fasting Conditions
Phase 1Diclofenac Sodium 75 mg Tablets Under Fasting Conditions
InflammationClinical Trials (1)
NCT00913887To Demonstrate the Relative Bioavailability of Diclofenac Sodium 75 mg Enteric-Coated Tablets Under Non-Fasting Conditions
Phase 1Bupropion HCI 300 mg Extended-Release Tablets EON
DepressionClinical Trials (1)
NCT00861939To Demonstrate the Relative Bioavailability of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions
Phase 1Indomethacin 75mg Extended-Release Capsules, Sandoz
InflammationClinical Trials (1)
NCT00858195A Relative Bioavailability Study of 75mg Indomethacin Extended-Release Capsules
Phase 1Loratadine 10 mg Tablets Under Fasting Conditions
AllergyClinical Trials (1)
NCT00946608To Demonstrate the Relative Bioavailability Study of Loratadine 10 mg Tablets
Phase 1Ramipril 10 mg Capsule
HypertensionClinical Trials (1)
NCT00946621To Demonstrate the Relative Bioavailability Study of Ramipril 10 mg Capsules Under Non-Fasting Conditions
Phase 1Bicalutamide 50 mg Film-Coated Tablets
Prostate CancerClinical Trials (1)
NCT00959335Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions
Phase 1Ramipril 10 Capsule
HypertensionClinical Trials (1)
NCT00946465To Demonstrate the Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fasting Conditions
Phase 1Lisinopril 40 mg Tablet
HypertensionClinical Trials (1)
NCT00883506To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablet Under Fasting and Fed
Phase 1Desipramine HCl 50 mg Tablets Cord Laboratories
DepressionClinical Trials (1)
NCT00914004To Demonstrate the Relative Bioequivalency of Comparing Single 100 mg Doses Of Cord's 50 mg Desipramine HCL Tablets To Merrell Dow's 50 mg Norpramin Tablets
Phase 1oxymorphone
PainClinical Trials (1)
NCT00857428Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted Conditions
Phase 1Azithromycin for Oral Suspension 200mg/5mL Eon Pharma, LLC
InfectionsClinical Trials (1)
NCT00875966Comparative Bioavailability Study of Azithromycin 200mg/5mL Suspension Following a 600mg Dose Under Fed Conditions
Phase 1Cefdinir 250 mg/5 ml Suspension
HealthyClinical Trials (1)
NCT00883883To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250 mg/5 ml Oral Suspension Fed Conditions
Phase 1Atenolol
AnginaClinical Trials (1)
NCT00946725To Demonstrate the Relative Bioavailability of Atenolol Tablets, 100 mg
Phase 1Generic Loteprednol Etabonate
Inflammation Following Ocular SurgeryClinical Trials (1)
NCT03531697Study of Loteprednol Etabonate in Adults Undergoing Bilateral Cataract Surgery
Phase 1Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg
AllergiesClinical Trials (1)
NCT00881127To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fasting Conditions
Phase 1Azithromycin Monohydrate 600 mg Tablets
InfectionClinical Trials (1)
NCT00865670To Demonstrate the Relative Bioavailability of Azithromycin 600 mg Tablets Under Fed Conditions
Phase 1Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 112 approved products, 48 clinical trials
Top TAs: Immunology, Infectious Diseases, Neurology
H-1B (2023): 2 approvals
Portfolio Health
Pre-Launch5 (4%)
LOE Approaching20 (18%)
Post-LOE87 (78%)
112 total products
Therapeutic Area Focus
Immunology
13 marketed
Infectious Diseases
8 marketed
Neurology
2 marketed
Cardiovascular
1 marketed
Dermatology
1 marketed
Marketed
Pipeline
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
2
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub